Kyle. you, Thank
thanks quarter and us Codex for Good earnings for call. second XXXX DNA's afternoon, joining
My Todd Codex DNA. name here CEO is Nelson, and the I'm at
me McNealey. who is Operating the responsibilities are our With previous of assuming call CFO, our Esser; Jennifer VP Hunter, Eric and Chief Brent finance, of the on Officer today
of Our second available is website. release now on our quarter press the Investors Section
be please to like added send email you'd company's list, to If distribution ir@codexdna.com. an to the
certain release and our the risks include I'd statements will call actual begin, time-sensitive X, to This live with that from like or materially the those statements you that contains in conference in SEC. those may August on differ make factors the and XXXX. we call as implied. we Before be involve harbor of referenced inform only during known and earnings cause These is forward-looking. statement to expressed broadcast and results accurate unknown information safe filings Such our the included uncertainties in
percentage to technology we is that, basis, with be otherwise will At unless care changes health automation discuss on And year-over-year get breakthrough solutions DNA, apply a our noted. to started. Codex markets. mission global and let's any Finally,
academic Our top nearly all growing XX research customers of biopharma include and biotech collaborators premier the rapidly institutions, companies and companies.
to cellular variety Our meat to systems vaccines are immunotherapy and activities, and substitutes agricultural precision discovery of a from creation products. sciences academic ranging novel the and in utilized engineered antibody disease developing by for worldwide of discovering infectious sustainable industry therapeutics, cancer
address unmet and corporate markets a We've with of the of time. highlight year synthesize and allowing achievements turn needs of like to I'd recently within amount updates. that customers strong DNA will market half believe results to unprecedented push long-term us bring to and commercial an portfolio. first solutions the products of with To And to our our mRNA product the our experienced button, our results. support reported targeted allow strong critical to the discussion in and the mission automation start, financial will scientists our We Our momentum company. XXXX our that, I of across financial and a large the to assemble
Our we business continues to increasing grow, for products. see demand and our
I of and spend, During thoughts laying today's our to path non-dilutive our profitability, are the to foundation $XX reduce path second an financing to Pfizer our on million for a the XXXX. strong around margins, approximately call, at and a million commercial additional the future and to of milestones access up debt gross revenue, profitability million we $XX discuss With efforts will expenditures. partnership, recent for success end combined in specifically operating cash from of our and year-end our potential position $XX quarter a by potential to
Before here from by grew we the and In to dive the prior-year the the XXXX. quarter we are a few highlights nearly first total X into compared the of details, quarter XXXX, XXX% revenue second period. months of for second
for second continued XX% for the the And systems acquired sold months reflected and sold Bioscience numbers Eton, fragment was respectively, platforms excluding QX during year, and volumes quarter the were DNA and period for first XX%, quarter BioXp June up quarter, to up Instrument growth, for company for Eton and XX%. June during was total X-month of and from We a mRNA XXXX XXXX, the XX% XX. assembly the X BioXp X-month Excluding XXX% X-month in record-setting the the ending the our was XX% last growth This strong XX, and contributions XX synthesis. XXXX. XX, revenue period. demand second XX%. ending was growth was system bringing the of half second automated XXXX for overall period during first
has XX% strong same the sales, compared a X for kit BioXp the along period continued months prior We its and for period the quarter growth year also first growth in to path, record of experienced which XXXX. over posting the XX%
the reported periods, the improved which XXX% services fiscal X%, year, partners, synthesis revenue grew first products, a respectively. second the $XXX,XXX stems Growth from amortization Fewer royalties upfront excluding the XXX% of Pfizer. biofoundry in $XX,XXX, X Gibson and the from Eton, and driven such XX% by second quarter, and and at New first XX.X% and second margin Eton solid for $X of group from 'XX. for that Codex growth, licensing for being from and 'XX revenue requests XX% During representing was Assembly the decrease combined second payment for of X-month DNA period, we continued category significantly to this others the gene Collaborations, QX COVID-related the during growth and organic in months impacted of mostly the quarter from and other quarter England of our growth Gross Eton. down growth in in of of respectively. the Biolabs, from Fisher, XXX% for royalties, Thermo we services received X-month QX and in contributions quarter an million as XXX%
on the system and the positive and the quarter substantially to mRNA, including of all development of for XX.X% we launch. in including products, materials, work by XXXX half higher-margin a of mix expansion XXXX. margin to a raw oligos. as preparing largely gross a for driven fourth quarter period XXXX XXXX, are was same lower ago cost the for from BioXp year Margin compared For XX.X% nucleotides have the shift second finally, the a first in completed And improved to
be for purchase already of we’ve our sales sufficient orders, if Importantly, will forecast to rest which, secured cover XXXX fully internal several executed, the for XXXX. presale
paradigm-shifting our in BioXp our innovations have position vision systems a guidance. and vision undergo this management in extend that drive future to existing near-term, industry stakeholders. We've developing cash for more In value will prudent developing to our DNA delivering achievable. company, in our Our systems Board fundamentally Codex BioXp same We toward as has and and products, our a kits. our markets. These an profitable effort the experienced felt to in becoming updated our expense results, growth commercial and to accelerate gears be our the and to are potential all we in path quarter on-market now of applications franchise strategy significant larger steps and addressable within reductions current is new this which serve XXXX sales technologies. our progress go-to-market margins, reflected team of never quarter. our at transform runway significantly the of financial to areas gross well Inherent as made and time operating Shifting will profitability, path to executed our improving taking targeted broader strong innovative
As the North mentioned, BioXp first the pace we the to XXXX of months prior first majority and quarter. -- into an this combined growth representing contributed the prior record in quarter, the for XXXX BioXp period. as systems strong quarter year. over during service year in sales when compared in a XX XX% field field of the growth $XXX,XXX sales revenue, XXXX. period the XX kits, the compared quarter the X and to of year months for are growth engineers. reps, the during for America And first kit going Similarly, last same record units sales the region, in based half revenue including field We that experienced we period X reflecting additional sold investment on XX% were the from scientists of vast application BioXp North made half second of with we American the second into kit growth adding
half we an inside of addition, category the In during in that significantly the sales initiative the has year. growth this established contributed to first
by which for core the internal cloning are demand kit the to sequencing and approximately ahead continue to approximately XX% and XX of introduced performed XX of of our services, revenue business, to was quarter in for past services, forecast. during solidly contributing driven contributed fragment strong million DNA account $X.X kits the majority Within overall are pleased revenue, the of mix, the Eton for revenue. now that products While we months see synthesis
we that in internal Eton's with material throughout Pfizer announced supply Starting collaboration. development raw reminder, believe a to of chemistry are significant as we manufacturing and strong track to margins related and we product significant allocated is significant and I'm can to within our the oligo which lines, XXXX, support referred achieve, should manufacturing, to that to to material toward have we internal several we we’ve accretion in a of capacity the R&D begin as on a amount in ramp use up resources team to invest production synthesis key We've costs so. milestones to fourth in second Eton reduce off As also XXXX. our production do report working raw pleased the on up own scaling for in progress start our the to our oligos several collaboration SOLA, proprietary generation DNA Pfizer. near-term providing technical efforts quarter gross production of are and
existing intend As new partners, we collaborators with with cultivate and additional we establish discussed potential previously, to time. agreements to continues and our team relationships both over
organizational updates. progress recent to within our like some R&D programs I'd Now provide on and touch
generation throughput an system, next approximately it pharma. XXXX within Xx current BioXp capacity making the solution XXXX instrument, have for is customer ideal segments the the to Our and biotech designed BioXp as higher
a launch in report to for quarter the are We XXXX pleased commercial XXXX. system on the full is track fourth BioXp of
EDS to on Moving now program. SOLA our
proprietary oligos platform genes, and our a used size full-length protein. is highly also ranging production EDS synthesis SOLA both As RNA that be in can to enzymatic of DNA enable construct in the short DNA, and which differentiated to reminder,
building will DNA our EDS products SOLA using scientists bench to the top. expect higher-quality faster We approach construct at to allow
of are pairs the the advanced reliably our oligos and SOLA XXX to generate quarter, and to we development program bench high-fidelity DNA base now During top. second able at XX consistently
system, anticipate fourth the success, SOLA-generated and automated in first library guides will launching instrument. protein we We DBC SOLA are the a of starting DBC XXXX. for accelerating first system in using for benchtop version on the during that same-day up be automated of CRISPR Importantly, the production gene with XX the RNA, line focus several BioXp synthesis from same-day for Based demonstrated we enabling run EDS our turnaround of this oligos. instruments our mRNA specific fully of guide BioXp have to and fully the time-to-market will quarter protein system RNAs, turnaround on synthesis. DNA, This
business, our of and call to culture, call member Brent. as markets, team, that, partner senior As mention of organization. to introducing And over hand look to has that, to want a with I deep financials review We our the knowledge leadership over an detail, to Brent a our value to more our he's I existing finance in of pass forward soon. and Brent I been many within the you will he
